FOLLOW THIS NEWS TO THE MONEY (ACTC) READ!
Advanced Cell Technology's CEO is bullish about company's advancements
Advanced Cell Technology’s CEO is bullish about company's advancements
Dec. 10, 2010 (Baystreet.ca) --
Several key announcements have pushed Advanced Cell Technology’s (OTCBB:ACTC) stock from just under a nickel in late November to an intraday high of $.20 during Wednesday’s session and volume has made it apparent that a growing crowd of day traders momentum players have now joined biotech investors in cheering on the small biotech.
The excitement around ACTC comes after a recent series of key positive announcements including the fact that the FDA granted orphan drug status to the micro-cap's patented embryonic stem cell derived treatment for specific forms of Macular Degeneration and blindness (Stargardt's Macular Dystrophy and Dry Age-related Macular Degeneration). The eye conditions destroy the pigmented layer of retina (retinal pigment epithelium) which is the pigmented cell layer just outside the neurosensory retina that nourishes retinal visual cells.
Advanced Cell Technology has shown success introducing the embryonic stem cell derived RPE cells into the eye in animal models and this resulted in 100% improvement with no side effects for more than 220 days. Human clinical trials are expected to start in the first quarter of 2011, and could potentially take only a few weeks to show positive results according to some analysts.
In addition, for only the second time in history (following Geron’s therapy for spinal cord injury), the FDA granted approval for clinical trials for a therapy derived from human embryonic stem cells.
BioMedReports: It appears that suddenly your company has a lot of attention given your news developments. What do you make of all the activity in your stock during recent days?
We anticipate the climb will continue for the upcoming days and weeks ahead.
We believe a price target will soon be announced and look forward in reaching that milestone for investors who help make this possible.
AI
